Read more about the article Somalia’s construction boom in Mogadishu gives women high ambitions
Somalia’s construction boom in Mogadishu gives women high ambitions

Somalia’s construction boom in Mogadishu gives women high ambitions

The women at the centre of Somalia's construction boomFardowsa HanshiBBC News, MogadishuAnthony Irungu / BBCFathi Mohamed Abdi (L) and Saadia Ahmed Omar (R) have overseen more than 30 multimillion-dollar projectsConstruction…

Continue ReadingSomalia’s construction boom in Mogadishu gives women high ambitions
Read more about the article Regeneron and Sanofi Announce Dupixent Outperformance over Xolair in Phase 4 EVEREST Trial Results for CRSwNP and Asthma
Regeneron and Sanofi Announce Dupixent Outperformance over Xolair in Phase 4 EVEREST Trial Results for CRSwNP and Asthma

Regeneron and Sanofi Announce Dupixent Outperformance over Xolair in Phase 4 EVEREST Trial Results for CRSwNP and Asthma

Dupixent surpassed Xolair in treating CRSwNP and asthma, improving symptoms and quality of life significantly.Quiver AI SummaryNew findings from the EVEREST Phase 4 trial presented at the 2025 EAACI Congress…

Continue ReadingRegeneron and Sanofi Announce Dupixent Outperformance over Xolair in Phase 4 EVEREST Trial Results for CRSwNP and Asthma
Read more about the article Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients
Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients

Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients

Lonvo-z showed a 98% reduction in HAE attacks for 10 patients over three-year follow-up, demonstrating promising safety and efficacy.Quiver AI SummaryIntellia Therapeutics has announced promising three-year follow-up data from its…

Continue ReadingIntellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients

End of content

No more pages to load